Bio-Thera Solutions, Ltd. (SHA:688177)
China · Delayed Price · Currency is CNY 20.21
-0.14 (-0.69%)
At close: May 12, 2026
Bio-Thera Solutions Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 980.25 | 935.22 | 743.01 | 704.41 | 455.13 | 836.58 |
Other Revenue | - | - | 0.15 | 0.38 | 0 | - |
| 980.25 | 935.22 | 743.17 | 704.79 | 455.13 | 836.58 | |
Revenue Growth (YoY) | 24.38% | 25.84% | 5.44% | 54.85% | -45.60% | 357.49% |
Cost of Revenue | 196.63 | 197.22 | 229.7 | 194.67 | 191.09 | 35.9 |
Gross Profit | 783.62 | 738 | 513.46 | 510.13 | 264.04 | 800.68 |
Selling, General & Admin | 354.98 | 336.29 | 269.62 | 201.3 | 174.24 | 215.45 |
Research & Development | 880.8 | 800.15 | 777.63 | 768.64 | 616.39 | 543.42 |
Other Operating Expenses | -48.86 | -52.18 | 5.02 | 4.91 | 3.34 | 2.17 |
Operating Expenses | 1,187 | 1,084 | 1,053 | 975.04 | 793.26 | 761.93 |
Operating Income | -403.3 | -346.27 | -539.04 | -464.91 | -529.22 | 38.75 |
Interest Expense | - | - | -20.55 | -10.38 | -0.06 | -0.78 |
Interest & Investment Income | 0.76 | 0.83 | 4.98 | 8.3 | 15.53 | 21.68 |
Currency Exchange Gain (Loss) | - | - | 0.68 | -0.15 | 1.86 | 1.47 |
Other Non Operating Income (Expenses) | 13.59 | 15.16 | -0.25 | -0.33 | -0.26 | -0.39 |
EBT Excluding Unusual Items | -388.96 | -330.28 | -554.18 | -467.47 | -512.15 | 60.74 |
Gain (Loss) on Sale of Investments | 0.44 | 0.55 | 3.45 | 6.97 | 14.53 | 11.9 |
Gain (Loss) on Sale of Assets | -1.78 | -1.72 | -0.51 | 0.03 | -0.07 | -0.02 |
Asset Writedown | 0.15 | -0.2 | - | - | - | - |
Other Unusual Items | - | - | 40.94 | 66.05 | 17.29 | 18.42 |
Pretax Income | -390.14 | -331.65 | -510.3 | -394.42 | -480.4 | 91.04 |
Income Tax Expense | 0.3 | 0.29 | - | 0.11 | 0 | 9.11 |
Net Income | -390.44 | -331.94 | -510.3 | -394.53 | -480.4 | 81.94 |
Net Income to Common | -390.44 | -331.94 | -510.3 | -394.53 | -480.4 | 81.94 |
Shares Outstanding (Basic) | 416 | 415 | 415 | 415 | 414 | 410 |
Shares Outstanding (Diluted) | 416 | 415 | 415 | 415 | 414 | 410 |
Shares Change (YoY) | 0.55% | 0.01% | -0.10% | 0.28% | 1.09% | 1.38% |
EPS (Basic) | -0.94 | -0.80 | -1.23 | -0.95 | -1.16 | 0.20 |
EPS (Diluted) | -0.94 | -0.80 | -1.23 | -0.95 | -1.16 | 0.20 |
Free Cash Flow | -311.83 | -203.86 | -182.5 | -723.01 | -671.64 | 158.38 |
Free Cash Flow Per Share | -0.75 | -0.49 | -0.44 | -1.74 | -1.62 | 0.39 |
Gross Margin | 79.94% | 78.91% | 69.09% | 72.38% | 58.01% | 95.71% |
Operating Margin | -41.14% | -37.03% | -72.53% | -65.96% | -116.28% | 4.63% |
Profit Margin | -39.83% | -35.49% | -68.67% | -55.98% | -105.55% | 9.79% |
Free Cash Flow Margin | -31.81% | -21.80% | -24.56% | -102.58% | -147.57% | 18.93% |
EBITDA | -294.19 | -242.01 | -454.21 | -383.34 | -448.35 | 108.87 |
EBITDA Margin | -30.01% | -25.88% | -61.12% | -54.39% | -98.51% | 13.01% |
D&A For EBITDA | 109.11 | 104.26 | 84.83 | 81.57 | 80.88 | 70.12 |
EBIT | -403.3 | -346.27 | -539.04 | -464.91 | -529.22 | 38.75 |
EBIT Margin | -41.14% | -37.03% | -72.53% | -65.96% | -116.28% | 4.63% |
Effective Tax Rate | - | - | - | - | - | 10.00% |
Revenue as Reported | - | - | 743.17 | 704.79 | 455.13 | 836.58 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.